147 related articles for article (PubMed ID: 9917506)
1. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Serra M; Maurici D; Scotlandi K; Barbanti-Brodano G; Manara MC; Benini S; Picci P; Bertoni F; Bacci G; Sottili S; Baldini N
Int J Oncol; 1999 Feb; 14(2):301-7. PubMed ID: 9917506
[TBL] [Abstract][Full Text] [Related]
2. [P-glycoprotein expression in osteosarcoma].
Pösl M; Grahl K; Amling M; Werner M; Ritzel H; Stenzel I; Hentz M; Winkler K; Delling G
Pathologe; 1996 Jan; 17(1):50-5. PubMed ID: 8685096
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.
Chan HS; Grogan TM; Haddad G; DeBoer G; Ling V
J Natl Cancer Inst; 1997 Nov; 89(22):1706-15. PubMed ID: 9390540
[TBL] [Abstract][Full Text] [Related]
5. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
[No Abstract] [Full Text] [Related]
6. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
7. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.
Park YB; Kim HS; Oh JH; Lee SH
Int Orthop; 2001; 24(6):307-10. PubMed ID: 11294418
[TBL] [Abstract][Full Text] [Related]
8. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
9. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 expression is correlated with increased survival of patients with osteosarcoma.
Akatsuka T; Wada T; Kokai Y; Kawaguchi S; Isu K; Yamashiro K; Yamashita T; Sawada N; Yamawaki S; Ishii S
Cancer; 2002 Mar; 94(5):1397-404. PubMed ID: 11920494
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein levels predict poor outcome in patients with osteosarcoma.
Hornicek FJ; Gebhardt MC; Wolfe MW; Kharrazi FD; Takeshita H; Parekh SG; Zurakowski D; Mankin HJ
Clin Orthop Relat Res; 2000 Apr; (373):11-7. PubMed ID: 10810457
[TBL] [Abstract][Full Text] [Related]
12. Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53.
Lacueva FJ; Calpena R; Medrano J; Teruel A; Mayol MJ; Graells ML; Camarasa MV; Perez-Vazquez MT; Ferragut JA
Cancer; 2000 Jul; 89(1):21-8. PubMed ID: 10896996
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo.
De Angelis P; Stokke T; Smedshammer L; Lothe RA; Lehne G; Chen Y; Clausen OP
Br J Cancer; 1995 Aug; 72(2):307-11. PubMed ID: 7640210
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
15. [Expression of the p53 protein in human osteosarcoma].
Nishikawa T; Yamamoto T; Mizuno K; Fujimori T; Maeda S; Ugai K
Nihon Seikeigeka Gakkai Zasshi; 1994 May; 68(5):400-6. PubMed ID: 8051467
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis.
Ralhan R; Swain RK; Agarwal S; Kaur J; Nath N; Sarkar G; Mathur M; Shukla NK
Int J Cancer; 1999 Feb; 84(1):80-5. PubMed ID: 9988237
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance and malignancy in human osteosarcoma.
Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N
Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
